Nutriband Reports 51% Revenue Growth, Advances Abuse-Deterrent Fentanyl Patch Toward FDA Approval
Nutriband Inc. achieved significant revenue growth and strengthened its financial position to advance AVERSA Fentanyl, potentially becoming the first global abuse-deterrent transdermal fentanyl product with estimated peak annual sales of $80-200 million.
Nutriband Inc. (NASDAQ: NTRB) reported substantial financial progress with revenue reaching $1.29 million for the six months ended July 31, 2025, representing a 50.87% year-over-year increase. The company maintains a strong cash position of $6.9 million, which management states will support the advancement of its lead product candidate, AVERSA Fentanyl. This financial strength comes at a critical time as the company prepares for a Type C FDA meeting scheduled for September 18.
The development pathway for AVERSA Fentanyl represents a significant regulatory advantage, as the New Drug Application will rely solely on data from a single Phase 1 Human Abuse Potential study. This approach eliminates the need for Phase 2 or Phase 3 clinical trials, potentially accelerating the approval process. If approved, the product would become the first and only abuse-deterrent transdermal fentanyl product available globally, addressing a critical need in pain management while combating opioid abuse.
Market projections for AVERSA Fentanyl indicate substantial commercial potential, with peak annual sales estimated between $80 million and $200 million. The company's second program, AVERSA Buprenorphine, also shows promising market prospects with projected peak annual sales of up to $130 million. These projections underscore the significant addressable market for abuse-deterrent transdermal technologies.
Revenue growth was primarily driven by the company's contract manufacturing subsidiary, Pocono Pharma, which contributed to record first-half performance. This diversified revenue stream provides financial stability while the company advances its proprietary drug development programs. The AVERSA technology platform, which can be incorporated into any transdermal patch, represents a versatile solution for preventing abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Additional information about Nutriband Inc. is available through the company's corporate communications at https://ibn.fm/NTRB. The development of abuse-deterrent formulations represents an important advancement in addressing the ongoing opioid crisis while maintaining access to essential pain management medications for legitimate patients.